Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603510 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02603510 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 27 participants.
The verdict
NCT02603510, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Primary Objective: * Assess the safety of SAR342434 and Humalog when used in external pumps. Secondary Objectives: * Intervals for infusion set changes. * Incidence of insulin pump alarms for infusion set occlusion. * Patient observation of infusion set occlusion. * Adverse events including bruising at the infusion site and injection site reactions.
Interventions
- DRUG insulin lispro
- DRUG SAR342434
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603510
The ClinicalTrials.gov registry entry for NCT02603510 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin lispro is the first listed.
NCT02603510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603510 about?
NCT02603510 is a clinical study titled "Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion". Primary Objective: * Assess the safety of SAR342434 and Humalog when used in external pumps. Secondary Objectives: * Intervals for infusion set changes. * Incidence of insulin pump alarms for infusion set occlusion. * Patient observation of infusion set occlusion. * Adverse events including bruis...
What is the current status of trial NCT02603510?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-11. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02603510?
The interventions under investigation include: insulin lispro (DRUG), SAR342434 (DRUG).
Who is sponsoring clinical trial NCT02603510?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.